Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JZP 385

Drug Profile

JZP 385

Alternative Names: CX-8998; JZP-385

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cavion
  • Developer Jazz Pharmaceuticals plc
  • Class Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action T-type calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy; Essential tremor
  • Preclinical Neuropathic pain

Most Recent Events

  • 12 Aug 2019 Jazz Pharmaceuticals acquires worldwide rights to CX 8998 from Cavion
  • 12 Aug 2019 Cavion has been acquired by Jazz Pharmaceuticals
  • 12 Aug 2019 Cavion plans a phase II trial for Tremors associated with Parkinson's disease in USA in 2020 (NCT03436953)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top